The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Open accessAbstract
BACKGROUND: Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity of atezolizumab. METHODS: In this phase 3 trial, we randomly assigned (in a 1:1 ratio) patients with untreated metastatic triple-negative breast cancer to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel; patients continued the intervention until disease progression or an unacceptable level of toxic effects occurred. Stratification factors were the receipt or nonreceipt of neoadjuvant or adjuvant taxane therapy, the presence or absence of liver metastases at baseline, and programmed death ligand 1 (PD-L1) expression at baseline (positive vs. negative). The two primary end points were progression-free survival (in the intention-to-treat population and PD-L1-positive subgroup) and overall survival (tested in the intention-to-treat population; if the finding was significant, then it would be tested in the PD-L1-positive subgroup). RESULTS: Each group included 451 patients (median follow-up, 12.9 months). In the intention-to-treat analysis, the median progression-free survival was 7.2 months with atezolizumab plus nab-paclitaxel, as compared with 5.5 months with placebo plus nab-paclitaxel (hazard ratio for progression or death, 0.80; 95% confidence interval [CI], 0.69 to 0.92; P=0.002); among patients with PD-L1-positive tumors, the median progression-free survival was 7.5 months and 5.0 months, respectively (hazard ratio, 0.62; 95% CI, 0.49 to 0.78; P<0.001). In the intention-to-treat analysis, the median overall survival was 21.3 months with atezolizumab plus nab-paclitaxel and 17.6 months with placebo plus nab-paclitaxel (hazard ratio for death, 0.84; 95% CI, 0.69 to 1.02; P=0.08); among patients with PD-L1-positive tumors, the median overall survival was 25.0 months and 15.5 months, respectively (hazard ratio, 0.62; 95% CI, 0.45 to 0.86). No new adverse effects were identified. Adverse events that led to the discontinuation of any agent occurred in 15.9% of the patients who received atezolizumab plus nab-paclitaxel and in 8.2% of those who received placebo plus nab-paclitaxel. CONCLUSIONS: Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup. Adverse events were consistent with the known safety profiles of each agent. (Funded by F. Hoffmann-La Roche/Genentech; IMpassion130 ClinicalTrials.gov number, NCT02425891 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, PD-L1 status by SP142 is the companion test for the use of atezolizumab in combination with a taxane for first-line therapy in triple-negative ABC, with a cut-off of 1% positive staining on immune cells.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“an analysis was conducted and presented, and showed an OS of 25 months versus 15.1 months favouring the atezolizumab arm.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the PD-L1 positive group, atezolizumab provided a PFS benefit of 7.5 versus 5 months with a HR of 0.62 (95% CI 0.49-0.78, P < 0.001).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“In the ITT population, atezolizumab provided a benefit in PFS of 7.2 versus 5.5 months with a HR of 0.8 (95% CI 0.69-0.92, P = 0.002).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“In the ITT population, there was no significant benefit in OS with the addition of atezolizumab; median OS was 21.3 months versus 17.6 months (HR 0.84; 95% CI 0.69-1.02, P = 0.08).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
In the citing paper
“to date, atezolizumab, in combination with chemotherapy, has been approved by the FDA for the treatment of squamous and nonsquamous NSCLC, small cell lung cancer, and PD-L1-positive triple-negative breast cancer (66)(67)(68)(69).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Hammond, M. E., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G. D., Goldstein, N. S., Hayes, M. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,217
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F. M., Poortmans, P. M., Rutgers, E. J. T., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,660
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Eenoo, F. V., Rouas, G., Francis, P. A., Crown, J. P., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,658
Self-citationPD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric‐Bernstam, F., Qiao, N., Wu, Y., Harrington, S. M., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akçakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,420
Flagged first, then by citations
Research works printed but not linked: 1
- Adams S Diamond JR Hamilton E et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol (in press).
Cited by
Sorted by citations
Items 701–800 of 1,010
Xu, Z., Shi, T., Mo, F., Yu, W., Shen, Y., Jiang, Q., Wang, F., & Liu, X. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202211505 · Cited by 59
Recent Developments and Anticancer Therapeutics of Paclitaxel: An Update
Thiruvengadam, M., Khalil, A. A., Rauf, A., Alhumaydhi, F. A., Aljohani, A. S. M., Javed, M. S., Khan, M. A., Khan, I. A., El-Esawi, M. A., Bawazeer, S., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612829666221102155212 · Cited by 59
Dent, R. A., Cescon, D. W., Bachelot, T., Jung, K. H., Shao, Z., Saji, S., Traina, T. A., Vuković, P., Mapiye, D. S., Maxwell, M. J., et al. (2023) · Future Oncology · doi:10.2217/fon-2023-0228 · Cited by 59
Self-citationChen, M., Yu, S., van der Sluis, T., Zwager, M. C., Schröder, C. P., van der Vegt, B., & van Vugt, M. A. T. M. (2024) · npj Breast Cancer · doi:10.1038/s41523-023-00609-z · Cited by 60
Mandal, K., Barik, G. K., & Santra, M. K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02400-z · Cited by 69
Yang, J., & Zhang, C. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1612 · Cited by 59
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 62
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
Isaacs, J. M., Anders, C. K., McArthur, H. L., & Force, J. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00833-4 · Cited by 60
Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients
Taskindoust, M., Thomas, S. M., Sammons, S. L., Fayanju, O. M., DiLalla, G. A., Hwang, E. S., & Plichta, J. K. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10227-3 · Cited by 58
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
Mazzotti, L., Gaimari, A., Bravaccini, S., Maltoni, R., Cerchione, C., Juan, M., González‐Navarro, E. A., Pasetto, A., Silva, D. N., Ancarani, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158590 · Cited by 64
Immunological nanomaterials to combat cancer metastasis
Pan, Y., Cheng, J., Zhu, Y., Zhang, J., Fan, W., & Chen, X. S. (2024) · Chemical Society Reviews · doi:10.1039/d2cs00968d · Cited by 58
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Fenn, K. M., & Kalinsky, K. M. (2019) · Drugs of today · doi:10.1358/dot.2019.55.9.3039669 · Cited by 57
Optimal Systemic Treatment for Early Triple-Negative Breast Cancer
Furlanetto, J., & Loibl, S. (2020) · Breast Care · doi:10.1159/000508759 · Cited by 63
Gatti-Mays, M. E., Karzai, F. H., Soltani, S. N., Zimmer, A. S., Green, J. E., Lee, M.-J., Trepel, J. B., Yuno, A., Lipkowitz, S., Nair, J. R., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0491 · Cited by 58
Chen, I. X., Newcomer, K., Pauken, K. E., Juneja, V. R., Naxerova, K., Wu, M. W., Pinter, M., Sen, D. R., Singer, M., Sharpe, A. H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002806117 · Cited by 55
Pilones, K. A., Hensler, M., Daviaud, C., Kraynak, J., Fucikova, J. P., Galluzzi, L., Demaria, S., & Formenti, S. C. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1830524 · Cited by 59
Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy
Wu, X., Li, Y., Liu, X., Chen, C., Harrington, S. M., Cao, S., Xie, T., Pham, T. T., Mansfield, A. S., Yan, Y., et al. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e01039 · Cited by 57
Fabian, K. P., Padget, M. R., Fujii, R., Schlom, J., & Hodge, J. W. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001691 · Cited by 59
Valencia-Sánchez, C., & Ζεκερίδου, Α. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.642800 · Cited by 58
Bioinformatics reveal macrophages marker genes signature in breast cancer to predict prognosis
Li, Y., Zhao, X., Liu, Q., & Liu, Y. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1914343 · Cited by 56
Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies
Zhao, N., & Rosen, J. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.07.010 · Cited by 58
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Henriques, B., Mendes, F., & Martins, D. F. (2021) · Biomedicines · doi:10.3390/biomedicines9111687 · Cited by 60
Epigenetic Therapies and Biomarkers in Breast Cancer
Brown, L. J., Achinger-Kawecka, J., Portman, N., Clark, S. J., Stirzaker, C., & Lim, E. (2022) · Cancers · doi:10.3390/cancers14030474 · Cited by 64
Gardner, A., Pulido, Á. D. M., Hänggi, K., Bazargan, S., Onimus, A., Kasprzak, A., Conejo-Garcia, J. R., Rejniak, K. A., & Ruffell, B. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003571 · Cited by 59
Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
Pham, J. P., Joshua, A. M., da Silva, I. P., Dummer, R., & Goldinger, S. M. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01385-6 · Cited by 61
Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC)
Mustafa, M., Abbas, K., Alam, M., Ahmad, W., Moinuddin, M., Usmani, N., Siddiqui, S. A., & Habib, S. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04772-6 · Cited by 58
Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial
Rodrigues, M. J., Vanoni, G., Loap, P., Dubot, C., Timperi, E., Minsat, M., Bazire, L., Durdux, C., Fourchotte, V., Laas, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39383-8 · Cited by 58
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
Ignatiadis, M., Bailey, A., McArthur, H. L., El-Abed, S., de Azambuja, E., Metzger, O., Chui, S. Y., Dieterich, M., Perretti, T., Shearer-Kang, E., et al. (2025) · JAMA · doi:10.1001/jama.2024.26886 · Cited by 65
Self-citationMyelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression
Sica, A., Guarneri, V., & Gennari, A. (2019) · Cell Stress · doi:10.15698/cst2019.09.197 · Cited by 56
‘Omics Approaches to Explore the Breast Cancer Landscape
Parsons, J., & Francavilla, C. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00395 · Cited by 58
Huemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 60
Cross‐Link‐Functionalized Nanoparticles for Rapid Excretion in Nanotheranostic Applications
Ma, Z., Wang, F., Zhong, Y., Salazar, F. B., Li, J., Zhang, M., Ren, F., Wu, A. M., & Dai, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008083 · Cited by 56
Goldinger, S. M., Buder‐Bakhaya, K., Lo, S., Forschner, A., McKean, M. A., Zimmer, L., Khoo, C. C. H., Dummer, R., Eroglu, Z., Buchbinder, E. I., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.022 · Cited by 61
Franzoi, M. A., & de Azambuja, E. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001112 · Cited by 57
Burotto, M., Zvirbule, Z., Mochalova, A., Runglodvatana, Y., Herraez-Baranda, L., Liu, S. N., Chan, P., Shearer-Kang, E., Liu, X., Tosti, N., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.009 · Cited by 56
Deng, L., Lu, D., Bai, Y., Wang, Y., Bu, H., & Zheng, H. Y. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0469 · Cited by 56
Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy
Baram, T., Rubinstein-Achiasaf, L., Ben-Yaakov, H., & Ben‐Baruch, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.614468 · Cited by 61
Li, C., Maishi, N., Annan, D. A., Young, M. F., Morimoto, H., Morimoto, M., Nam, J.-M., Hida, Y., & Hida, K. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01423-w · Cited by 59
Lee, S.-Y., Shim, H. S., Ahn, B., Lim, S. M., Kim, H. R., Cho, B. C., & Hong, M. H. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03052-w · Cited by 52
Shi, Y., Wei, W., Li, L., Wei, Q., Jiang, F., Xia, G., & Yu, H. (2021) · Bioengineered · doi:10.1080/21655979.2021.2006552 · Cited by 56
Goh, P. K., Wiede, F., Zeissig, M. N., Britt, K. L., Liang, S., Molloy, T., Goode, N., Xu, R., Loi, S., Müller, M. M., et al. (2022) · Science Advances · doi:10.1126/sciadv.abk3338 · Cited by 56
Self-citationLin, Y., Wilk, U., Pöhmerer, J., Hörterer, E., Höhn, M., Luo, X., Mai, H., Wagner, E., & Lächelt, U. (2022) · Small · doi:10.1002/smll.202205318 · Cited by 58
Guo, B., Qu, Y., Sun, Y., Zhao, S., Yuan, J., Zhang, P., Zhong, Z., & Meng, F. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.01.014 · Cited by 56
“40% MDSCs yielding low reponse rate of TNBC patients to immune therapy [17,43].”
BackgroundZhang, X., Zhuge, J., Liu, J., Xia, Z., Wang, H., Gao, Q., Jiang, H., Qu, Y., Fan, L., Ma, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1153423 · Cited by 56
A Paclitaxel Prodrug with Copper Depletion for Combined Therapy toward Triple-Negative Breast Cancer
Hao, D., Meng, Q., Li, C., Lu, S., Xiang, X., Pei, Q., Jing, X., & Xie, Z. (2023) · ACS Nano · doi:10.1021/acsnano.3c01792 · Cited by 58
Digital Pathology for Better Clinical Practice
Hijazi, A., Bifulco, C. B., Baldin, P., & Galon, J. (2024) · Cancers · doi:10.3390/cancers16091686 · Cited by 60
Chen, L., Li, H., Zhang, H., Yang, H., Qian, J., Li, Z., Ren, Y. T., Wang, S., Fu, P., Yang, H., et al. (2024) · JAMA · doi:10.1001/jama.2024.23560 · Cited by 63
Cheung, C. C., Barnes, P. J., Bigras, G., Boerner, S. L., BUTANY, J. W., Calabrese, F., Couture, C., Deschênes, J., El-Zimaity, H. M. T., Fischer, G., et al. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000800 · Cited by 57
Breast cancer vaccines: Heeding the lessons of the past to guide a path forward
Solinas, C., Aiello, M. M., Migliori, E., Willard-Gallo, K. E., & Emens, L. A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101947 · Cited by 57
Self-citationChi, C., Lao, Y., Ahmed, A. H. R., Benoy, E. C., Li, C., Dereli‐Korkut, Z., Fu, B. M., Leong, K. W., & Wang, S. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000880 · Cited by 60
Smart Nanoparticles for Chemo-Based Combinational Therapy
Shrestha, B., Wang, L., Brey, E. M., Romero, G., & Tang, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060853 · Cited by 58
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
Formenti, S. C., Hawtin, R. E., Dixit, N., Evensen, E., Lee, P., Goldberg, J. D., Li, X., Vanpouille-Box, C., Schaue, D., McBride, W. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0633-x · Cited by 53
Chia, S., Bedard, P. L., Hilton, J. F., Amir, E., Gelmon, K. A., Goodwin, R. A., Villa, D. R., Cabanero, M., Tu, D., Tsao, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0321 · Cited by 56
Early stage triple negative breast cancer: Management and future directions
Chaudhary, L. N. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.05.006 · Cited by 57
Saini, K. S., Punie, K., Twelves, C. J., Bortini, S., de Azambuja, E., Anderson, S., Criscitiello, C., Awada, A. H., & Loi, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1936494 · Cited by 58
Self-citationThe Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
Retecki, K., Seweryn, M., Graczyk‐Jarzynka, A., & Bajor, M. (2021) · Cancers · doi:10.3390/cancers13236012 · Cited by 56
Targeting triple-negative breast cancer: A clinical perspective
POPOVIC, L. S., Matovina-Brko, G., Popovic, M., Punie, K., Cvetanović, A., & Lambertini, M. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028525 · Cited by 57
Schmid, P., Turner, N. C., Barrios, C. H., Isakoff, S. J., Kim, S., Sablin, M., Saji, S., Savas, P. S., Vidal, G. A., Oliveira, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2084 · Cited by 55
Self-citationTherapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 57
Xie, X., Zhang, J., Zhongyuan, S., Liu, W., Hu, X., Qie, C., Chen, W., Wang, Y., Wang, L. L., Jiang, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563044 · Cited by 57
Immune-related biomarkers in triple-negative breast cancer
Zhang, J., Tian, Q., Zhang, M., Wang, H., Wu, L., & Yang, J. (2021) · Breast Cancer · doi:10.1007/s12282-021-01247-8 · Cited by 54
Si, Y., Yue, J., Liu, Z., Li, M., Du, F., Wang, X., Dai, Z., Hu, N., Ju, J., Gao, S., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s297933 · Cited by 52
Wang, Q., Xu, M., Sun, Y., Chen, J., Chen, C., Qian, C., Chen, Y., Cao, L., Xu, Q., Du, X., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00354 · Cited by 54
Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
Pogoda, K., Niwińska, A., Sarnowska, E. A., Nowakowska, D., Jagiełło-Gruszfeld, A., SIEDLECKI, J. A., & Nowecki, Z. I. (2020) · Journal of Oncology · doi:10.1155/2020/8545643 · Cited by 54
Qiu, P., Guo, Q., Yao, Q., Chen, J., & Lin, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.736030 · Cited by 53
“Immune checkpoint blockade monotherapy and immunotherapy in combination with chemotherapy have been reported to achieve encouraging results in treatment of some subtypes of breast cancer (31, 32).”
IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment
Felcher, C. M., Bogni, E. S., & Kordon, E. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031809 · Cited by 60
Assidicky, R., Tokat, Ü. M., Tarman, I. O., Saatci, Ö., Ersan, P. G., Raza, U., Oğul, H., Riazalhosseini, Y., Can, T., & Şahin, Ö. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06569-5 · Cited by 55
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi, M., Pilavaki, P., Constantinidou, A., & Stylianopoulos, T. (2022) · Theranostics · doi:10.7150/thno.72800 · Cited by 59
Triple-Negative Breast Cancer: Molecular Particularities Still a Challenge
Varzaru, V. B., Vlad, T., Popescu, R., Vlad, C. S., Moatar, A. E., & Cobec, I. M. (2024) · Diagnostics · doi:10.3390/diagnostics14171875 · Cited by 55
“The efficacy of the antibody–drug conjugate sacituzumab govitecan was demonstrated in the ASCENT trial for patients with metastatic TNBC [21,22,85–87,91 Reducing the risk of recurrence in TNBC is a crucial focus of treatment strategies, given the aggressive nature and higher recurrence rates…”
Li, G., Ma, X., Sui, S., Chen, Y., Li, H., Liu, L., Zhang, X., Zhang, L., Hao, Y., Yang, Z., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03200-x · Cited by 54
König, L., Mairinger, F. D., Hoffmann, O., Bittner, A., Schmid, K. W., Kimmig, R., Kasimir‐Bauer, S., & Bánkfalvi, Á. (2019) · BMC Cancer · doi:10.1186/s12885-019-5320-2 · Cited by 54
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Tunger, A., Sommer, U. J., Wehner, R., Kubasch, A. S., Grimm, M., Bachmann, M. P., Platzbecker, U., Bornhäuser, M., Baretton, G. B., & Schmitz, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101534 · Cited by 53
Chan, J. J., Tan, T. J., & Dent, R. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919880429 · Cited by 54
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
Kurozumi, S., Inoue, K., Matsumoto, H., Fujii, T., Horiguchi, J., Oyama, T., Kurosumi, M., & Shirabe, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-52944-6 · Cited by 53
Drug Repurposing for Triple-Negative Breast Cancer
Ávalos-Moreno, M., López-Tejada, A., Blaya-Cánovas, J. L., Cara, F. E., González-González, A., Lorente, J. A., Sánchez‐Rovira, P., & Granados-Principal, S. M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040200 · Cited by 60
Keenan, T. E., Li, T., Vallius, T., Guerriero, J. L., Tayob, N., Kochupurakkal, B. S., Davis, J. A., Pastorello, R., Tahara, R. K., Anderson, L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3089 · Cited by 57
Self-citationPredictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
Sivapiragasam, A., Kumar, P. A., Sokol, E. S., Albacker, L. A., Killian, J. K., Ramkissoon, S. H., Huang, R. S. P., Severson, E. A., Brown, C. A., Danziger, N. A., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3550 · Cited by 54
Nesbitt, H., Logan, K. A., Thomas, K. G., Callan, B., Gao, J., McKaig, T., Taylor, M., Love, M., Stride, E., McHale, A. P., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.003 · Cited by 55
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
Wu, B. M., Sternheim, N., Agarwal, P., Suchomel, J., Vadhavkar, S., Bruno, R., Ballinger, M. D., Bernaards, C. A., Chan, P., Ruppel, J., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13127 · Cited by 56
Marazzi, F., Orlandi, A., Manfrida, S., Masiello, V., Leone, A. D., Massaccesi, M., Moschella, F., Franceschini, G., Bria, E., Gambacorta, M. A., et al. (2020) · Cancers · doi:10.3390/cancers12092390 · Cited by 52
Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells
Samuel, S. M., Varghese, E., Koklesová, L., Líšková, A., Kubatka, P., & Büsselberg, D. (2020) · Cancers · doi:10.3390/cancers12092482 · Cited by 58
Wang, H., Ma, H., Sové, R. J., Emens, L. A., & Popel, A. S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002100 · Cited by 59
Self-citationExploiting bone niches: progression of disseminated tumor cells to metastasis
Muscarella, A. M., Aguirre, S., Hao, X., Waldvogel, S. M., & Zhang, X. H.-F. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143764 · Cited by 56
Tian, T., Zhao, Y., Zheng, J., Jin, S., Liu, Z., & Wang, T. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.017 · Cited by 53
Wang, Z., Wang, F., Ding, X., Li, T., Wang, H., Gao, Y., Wang, W., Liu, Y., Chen, X., & Shen, K. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.016 · Cited by 52
Clinical trials of immunotherapy in triple-negative breast cancer
Howard, F. M., Pearson, A. T., & Nanda, R. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06665-6 · Cited by 54
Maule, J. G., Clinton, L. K., Graf, R. P., Xiao, J., Oxnard, G. R., Ross, J. S., & Huang, R. S. P. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005573 · Cited by 53
Decoding Roles of Exosomal lncRNAs in Tumor-Immune Regulation and Therapeutic Potential
Zhang, W.-Q., Yan, Y., Peng, J., Thakur, A., Bai, N., Yang, K., & Xu, Z. (2022) · Cancers · doi:10.3390/cancers15010286 · Cited by 53
“Therefore, the application of immune checkpoint inhibitors may block the exosomal lncRNA-mediated receptor-ligand interaction between tumor and immune cells, thus enhancing anti-tumor immunity [121].”
BackgroundFucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota
Li, H., Dong, T., Tao, M., Zhao, H., Lan, T., Yan, S., Gong, X., Hou, Q., Ma, X., & Song, Y. (2024) · Food & Function · doi:10.1039/d3fo04807a · Cited by 53
Force, J. M., Leal, J. H. S., & McArthur, H. L. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0634-5 · Cited by 52
Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
D’Abreo, N., & Adams, S. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0216-2 · Cited by 53
Self-citationLi, Y., Zhou, Q., Song, Q., Wang, R., Lyu, S., Guan, X., Zhao, Y., & Wu, J.-P. (2020) · Journal of Immunology Research · doi:10.1155/2020/3948928 · Cited by 53
So, J. Y., Skrypek, N., Yang, H. H., Merchant, A. S., Nelson, G. W., Chen, W.-D. D., Ishii, H., Chen, J. M., Hu, G., Achyut, B. R., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3339 · Cited by 53
Molecular Biological Features of Nottingham Histological Grade 3 Breast Cancers
Takahashi, H., Oshi, M., Asaoka, M., Yan, L., Endo, I., & Takabe, K. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08608-1 · Cited by 55
Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Benítez, J. C., Remón, J., & Besse, B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3255 · Cited by 53
O’Meara, T. A., Marczyk, M., Qing, T., Yaghoobi, V., Blenman, K., Cole, K. S., Pelekanou, V., Rimm, D. L., & Pusztai, L. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00350 · Cited by 54
Zhang, W., Shen, Y., Huang, H., Pan, S., Jiang, J., Chen, W., Zhang, T., Zhang, C., & Ni, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01779 · Cited by 58
Dougan, M. L., Blidner, A. G., Choi, J. N., Cooksley, T., Glezerman, I. G., Ginex, P., Girotra, M., Gupta, D., Johnson, D. B., Shannon, V. R., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05707-3 · Cited by 53
Oshi, M., Katsuta, E., Yan, L., Ebos, J. M. L., Rashid, O. M., Matsuyama, R., Endo, I., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12051148 · Cited by 52
Metadata
- Authors
- Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., Henschel, V., Molinero, L., Chui, S. Y., Funke, R., Husain, A., Winer, E. P., Loi, S., & Emens, L. A.
- Affiliations
- Queen Mary University of London (GB)
- From the Barts Cancer Institute, Queen Mary University of London, London (P.S.); Perlmutter Cancer Center, New York University School of Medicine, New York (S.A.); the Department of Medicine, University of California, San Francisco, San Francisco (H.S.R.), and Genentech, South San Francisco (L.M., S.Y.C., R.F.) — both in California; University Hospital Heidelberg, Heidelberg, Germany (A.S.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul,...
- Seoul National University (KR)
- F. Hoffmann-La Roche AG (CH)
- The University of Melbourne (AU)
- Johns Hopkins University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2108-2121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2897422388
- Cited by
- 4,350
- References
- 32
- Citations by year
- 2026: 310 · 2025: 409 · 2024: 453 · 2023: 562 · 2022: 648 · 2021: 825 · 2020: 723 · 2019: 397 · 2018: 17
- FWCI
- 148.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche/Genentech
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- atezolizumab, nab-paclitaxel, triple-negative breast cancer, metastatic breast cancer, PD-L1 expression, immune checkpoint inhibitors, combination chemotherapy, progression-free survival, overall survival, liver metastasis, immune-related adverse events, PD-1/PD-L1 inhibitors
- MeSH terms
- Progression-Free Survival, Adult, Aged, Albumins, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Middle Aged, Survival Analysis, Paclitaxel, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
